NR3C1 and amyotrophic lateral sclerosis: To assess the functional consequences of such an alternative mode of action, we compared KH-103 to MIF, a non-selective GR antagonist with cross-reactivity with progesterone and, to a lesser extent, androgen receptors, and to CORT113176, a promising selective non-steroid GR modulator with partial agonistic actions, currently in a phase 2 trial for Amyotrophic Lateral Sclerosis (ALS)37.